Latham & Watkins and Mazanti-Andersen represented Ascendis Pharma A/S in the transaction.Ascendis Pharma A/S (Nasdaq: ASND) has announced the pricing of its underwritten public offering of 2,500,000…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Laura Testa
…
This content is for Standard 1 Year members only. LoginJoin Now